School of Medicine and Health Sciences Poster Presentations
Not to be Overlooked: The Need for Increased Dialogue Between Patient and Provider Surrounding Medical Foods in IBD
Poster Number
147
Document Type
Poster
Status
Medical Student
Abstract Category
Clinical Specialties
Keywords
Ulcerative Colitis, Crohn's, Medical Food
Publication Date
Spring 2018
Abstract
Background
Medical foods are treatments with growing evidence for use in a variety of gastrointestinal diseases. They are safe and have proven efficacy in helping to manage inflammatory bowel disease (IBD). They can be used as monotherapy or in addition to traditional therapies. While medical foods offer new, evidence-based options to treat IBD, physician awareness of them remains uncertain. We examined the frequency with which gastroenterologists discussed their use for IBD management and explored associations with gender or race.
Methods
A retrospective review of all IBD patients seen at an urban university gastroenterology practice in a 6-month period was performed. There were no exclusion factors. Patient age, gender, ethnicity, and disease type were obtained. Records were evaluated for discussions about medical foods as IBD therapy. The associations between discussion of medical foods and gender or race were analyzed with a Chi-square test.
Results
268 records were reviewed. Of those, 118 were men and 150 were women, with a mean age of 43. 80 were Black, 143 White, 6 Latino, 10 Asian, and 29 other. 158 had a diagnosis of Crohn’s and 109 had ulcerative colitis (UC), while 1 had indeterminate colitis. 8 (3%) in the cohort had a documented discussion about using medical foods to treat IBD. 6 discussed VSL#3 (2 Crohn’s, 4 UC), while 2 discussed Ensure (2 Crohn’s). There was no association between discussion of medical foods and gender (P=0.3) or race (P=0.9).
Conclusion
Medical foods are emerging in IBD management, with new evidence supporting their use in a diversity of clinical settings. While previously unclear, our study demonstrates that few IBD patients have documented discussions about medical foods. Though some discussions about medical foods may be undocumented, that only 3% of patients had documented discussions suggests clinicians are missing an opportunity to utilize this therapeutic option. Given the growing evidence for therapeutic use of medical foods in IBD, physicians should increase the visibility of their use.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Open Access
1
Not to be Overlooked: The Need for Increased Dialogue Between Patient and Provider Surrounding Medical Foods in IBD
Background
Medical foods are treatments with growing evidence for use in a variety of gastrointestinal diseases. They are safe and have proven efficacy in helping to manage inflammatory bowel disease (IBD). They can be used as monotherapy or in addition to traditional therapies. While medical foods offer new, evidence-based options to treat IBD, physician awareness of them remains uncertain. We examined the frequency with which gastroenterologists discussed their use for IBD management and explored associations with gender or race.
Methods
A retrospective review of all IBD patients seen at an urban university gastroenterology practice in a 6-month period was performed. There were no exclusion factors. Patient age, gender, ethnicity, and disease type were obtained. Records were evaluated for discussions about medical foods as IBD therapy. The associations between discussion of medical foods and gender or race were analyzed with a Chi-square test.
Results
268 records were reviewed. Of those, 118 were men and 150 were women, with a mean age of 43. 80 were Black, 143 White, 6 Latino, 10 Asian, and 29 other. 158 had a diagnosis of Crohn’s and 109 had ulcerative colitis (UC), while 1 had indeterminate colitis. 8 (3%) in the cohort had a documented discussion about using medical foods to treat IBD. 6 discussed VSL#3 (2 Crohn’s, 4 UC), while 2 discussed Ensure (2 Crohn’s). There was no association between discussion of medical foods and gender (P=0.3) or race (P=0.9).
Conclusion
Medical foods are emerging in IBD management, with new evidence supporting their use in a diversity of clinical settings. While previously unclear, our study demonstrates that few IBD patients have documented discussions about medical foods. Though some discussions about medical foods may be undocumented, that only 3% of patients had documented discussions suggests clinicians are missing an opportunity to utilize this therapeutic option. Given the growing evidence for therapeutic use of medical foods in IBD, physicians should increase the visibility of their use.